Provided by Tiger Trade Technology Pte. Ltd.

Outlook Therapeutics, Inc.

0.5900
+0.01803.15%
Pre-market: 0.59000.00000.00%08:56 EDT
Volume:4.24M
Turnover:2.51M
Market Cap:143.37M
PE:-0.79
High:0.6066
Open:0.6023
Low:0.5800
Close:0.5720
52wk High:2.54
52wk Low:0.1611
Shares:243.00M
Float Shares:198.00M
Volume Ratio:0.72
T/O Rate:2.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7479
EPS(LYR):-1.7940
ROE:-3.65%
ROA:-143.17%
PB:-13.80
PE(LYR):-0.33

Loading ...

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of Lytenava™

THOMSON REUTERS
·
Aug 14

Press Release: Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of Lytenava(tm)

Dow Jones
·
Aug 14

S&P 500 Hits New Record High Following PPI Data: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone

Benzinga Earnings
·
Aug 14

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga Earnings
·
Aug 14

U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce

Reuters
·
Aug 14

Top Premarket Decliners

MT Newswires Live
·
Aug 13

Outlook Therapeutics Prices $55 Million Securities Offering; Shares Down Pre-Bell

MT Newswires Live
·
Aug 13

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

THOMSON REUTERS
·
Aug 13

Outlook Therapeutics - Combined Public Offering Price Per Share and Warrant is $0.99

THOMSON REUTERS
·
Aug 13

Outlook Therapeutics - Terminates May 13, 2026 Prospectus Supplement for ATM Offering Agreement with H.C. Wainwright

Reuters
·
Aug 13

Outlook Therapeutics - Terminates May 13, 2026 Prospectus Supplement for Atm Offering Agreement with H.c. Wainwright - SEC Filing

THOMSON REUTERS
·
Aug 13

Outlook Therapeutics Launches Public Offering with Accompanying Stock Purchase Warrants

Reuters
·
Aug 13

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

THOMSON REUTERS
·
Aug 13

Outlook Therapeutics - Proceeds to Support Lytenava U.S. Launch, Working Capital, and Corporate Purposes

THOMSON REUTERS
·
Aug 13

Outlook Therapeutics Inc Expected to Post a Loss of 9 Cents a Share - Earnings Preview

Reuters
·
Aug 12

Outlook Therapeutics Updates Financial Calendar for Quarterly Results Call and Webcast

Reuters
·
Aug 06

OTLK, HBAN, CORT, CAPR, GOSS Trending With Analysts

TIPRANKS
·
Aug 01

Outlook Therapeutics Director Faisal Ghiath Sukhtian Acquires 95,398 Common Shares for $99,962.34

Reuters
·
Jul 30

Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Gossamer Bio (GOSS)

TIPRANKS
·
Jul 28

Outlook Therapeutics upgraded to Buy from Neutral at BTIG

TIPRANKS
·
Jul 27